Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of SCOHIA’s internally discovered novel Nrf2 activators, for prevention and/or treatment of eye and skin diseases.
Lead Product(s): KTX-101
Therapeutic Area: Ophthalmology Product Name: SCO-116
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kuria Therapeutics
Deal Size: $67.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 27, 2022